Here at MS Money Moves, we seek to provide the research edge that retail investors need in order to be successful in these volatile markets. One thing we know in the world of investing in biotechnology is that nothing is certain. We firmly believe that strong, sound fundamentals are an essential aspect of a biotechnology company. Then, we look at other aspects of companies, such as institutional investors and upcoming catalysts. Now that we have touched upon this oversimplified approach to investing, let’s take a look at some new research and Intel. The deadline that requires institutional investors to update us on purchases and sales they made in the first quarter has passed, allowing us to see where the hallowed investors have stashed their money. The one downside of this, is that it is retrospective in nature, meaning the current status to the institutional investor could be vastly different from March 31st (the end of the first quarter). However, these filings can help key us into some of the companies whales are betting on. As such, we canvassed the first quarter filings of our favorite whales to identify potentially promising small cap biotechnology companies. Here is what we found:
You must log in to post a comment.